Amplitude Surgical – 2022-23 Annual Results

Sales of €100.2 Million and EBITDA of €26.1 Million - Seite 2

General & Administrative costs

13.3

11.5

15.4%

Research & Development costs

1.8

1.8

-3.3%

EBITDA

 

26.1

22.0

18.7%

as a % of sales

 

26.1%

25.1%

+95 bps

Recurring operating profit/loss

10.3

6.8

 

Non-recurring operating income and expenses

-2.3

-1.8

 

Operating profit/loss

8.0

4.9

 

Financial profit/loss

-14.0

-6.6

 

Current and deferred tax

-0.8

-1.2

 

Profit/loss from discontinued activities, after tax

45.3

-2.0

 

Net profit/loss - Group share

39.2

-4.4

 

 

 

 

 

 

Net financial debt

69.3

118.0

 

Net cash position at end of period

37.2

21.0